Posted by Iain Butler, Partner
Royds Withy King helps Oxford Genetics to secure £6.5m funding deal
Corporate lawyers from Royds Withy King have helped Oxford Genetics, an Oxford based biotechnology business which specialises in biological drug development, to secure a £6.5m syndicated investment which will further secure its position as a market-leading innovator of synthetic biology-based technologies. The cash injection values Oxford Genetics, which is based at Oxford Science Park, at £30.5m.
Our life sciences legal specialists advised Ryan Cawood, founder and CEO of Oxford Genetics and his team on the terms of their latest syndicated round comprising Mercia Technologies, Invesco Asset Management and Canaccord Genuity.
Iain Butler, Corporate Partner at our Oxford office, led on the deal and was assisted by Jennifer Sampson and Emma Hough.
Iain said: “We were very pleased to have the opportunity to work with Ryan and his team on this latest round of syndicated investment funding which will further fuel Oxford Genetics’ ground-breaking work in the fields of cell and gene therapy. Oxfordshire has a growing hub of world class life sciences businesses and it is a privilege to be involved with many of them.”
Commenting on the funding deal, Ryan Cawood said: “We have enjoyed a long-standing relationship with Royds Withy King. We were very pleased with the support they provided throughout the process and their expertise was invaluable in helping us to negotiate our latest funding round.
“This significant investment will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering. Through our continued investment in automation and optimising our commercialisation strategy, we aim to maximise shareholder value and exceed our ambitious growth targets.”
We are heavily involved with the life sciences sector. Last Thursday, we held a ‘Life After Brexit’ event at The Ashmolean Museum in Oxford, which sparked rich discussions on the opportunities to ensure the UK remains a leading place in the world to develop and launch innovative medicines, technologies and diagnostics.
Over 70 guests turned up to hear Professor Chas Bountra, Pro Vice Chancellor, Innovation, at Oxford University, and Bill Haynes, Head of Site at Novo Nordisk Research Centre in Oxford talk about the issues, before taking part in a lively question and answer discussion chaired by Labour peer Stewart Wood with panellists including Priya Mande, Chief Operating Officer from PsiOxus, and Stephen Conway, Director of Research Services at the University of Oxford. They were also joined by our London Partner Claus Anderson, who heads up our Brexit taskforce and life sciences team.
We also support a series of initiatives at Harwell Campus as well as events on innovation in science and technology run by The Bessemer Society.
If you have any enquiries, please contact Iain Butler on:
01865 268 666 Email us
Corporate & Commercial
Keeping you informed about Corporate & Commercial news, events and opinion.